## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($311.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Elevance Health expands virtual assistant access for care services**
- Source: Yahoo | 20251208T101028 | Bullish | Relevance: 98%
-  Elevance Health has expanded the availability of its virtual assistant to nearly 22 million members with commercial health plans, aiming to simplify obtaining information, clarifying benefits, and locating care services. The virtual assistant utilizes conversational technology and is accessible via the company's affiliated health plan websites and the Sydney Health app, with early data indicating high user satisfaction. Plans are in place to extend access to Medicare members in 2026, contingent on state approvals.

**2. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: Fox 59 | 20251209T160742 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (ELV) concerning potential corporate wrongdoing by the company and its officers/directors. The firm encourages investors who purchased Elevance securities before April 18, 2024, and still hold them, to contact them for more information and to assist in the investigation. The representation of investors in class actions is on a contingency fee basis with no upfront cost to the investors.

**3. Elevance Health, Inc. (ELV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation**
- Source: KLAS 8 News Now | 20251207T160812 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Elevance Health, Inc. (NYSE: ELV) on behalf of investors who purchased securities before April 18, 2024, and still hold them. The investigation seeks to determine if Elevance and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: WETM | 20251209T160926 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV). The firm encourages investors who purchased Elevance securities before April 18, 2024, and still hold them, to join the investigation. Interested parties can find more information or assist the investigation by visiting the firm's website or contacting their client relations managers.

**5. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: WNTZ-TV FOX 48 | 20251209T160807 | Neutral | Relevance: 97%
- Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV) and its officers/directors. Investors who purchased Elevance securities before April 18, 2024, and still hold them, are encouraged to contact the firm for more information and to assist in the investigation. The firm represents investors on a contingency fee basis in securities fraud class actions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 7.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.3B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.1 |
| Current P/E | 11.0 |
| YoY Growth | -9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.6% (minimal 5-day change). Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.56), confirming momentum. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.55% (CS: 42) | Neutral |
| RSI_14 | 50.5 | Neutral |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 0.921x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $329.81
- **Stop Loss:** $311.95 (5.4% risk)
- **Target:** $347.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $5,276.96
- **Portfolio %:** 5.28%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*